Free Trial

Oragenics Q3 2023 Earnings Report

Oragenics logo
$0.36 -0.02 (-5.53%)
(As of 12/20/2024 05:45 PM ET)

Oragenics EPS Results

Actual EPS
-$0.85
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oragenics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oragenics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

Oragenics Earnings Headlines

I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)
See More Oragenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email.

About Oragenics

Oragenics (NYSE:OGEN), a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

View Oragenics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings